Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye drop aims to beat standard glaucoma treatment

NCT ID NCT04630808

Disease control Sponsor: Nicox Ophthalmics, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 3 trial tested whether a new eye drop called NCX 470 can lower eye pressure better than the standard drop latanoprost in people with open-angle glaucoma or ocular hypertension. About 696 participants used one drop in each eye every evening for up to 12 months. The study compared how much eye pressure dropped at different times of day over several weeks and months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
NCX 470 eye drops
What this could lead to
If it works, this could offer a new once-daily eye drop option to lower eye pressure in people with glaucoma or high eye pressure.
What could go wrong
This is a late-stage trial, but NCX 470 must still prove it works better than the standard treatment latanoprost. Side effects or lack of added benefit could limit its use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

696 people

The number who actually took part.

Started

Nov 2020

Finished

Jun 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 84 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of open-angle glaucoma or ocular hypertension in both eyes * Qualifying IOP at 3 time points through the day at 2 visits following washout of IOP-lowering medication, if applicable * Qualifying best-corrected visual acuity in each eye * Ability to provide informed consent and follow study instructions Exclusion Criteria: * Narrow anterior chamber angles or disqualifying corneal thickness in either eye * Clinically significant ocular disease in either eye * Previous complicated surgery or certain types of glaucoma surgery in either eye * Incisional ocular surgery or severe trauma in either eye within the past 6 months * Uncontrolled systemic disease

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ocular hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ocular hypertension open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ocular hypertension Open angle glaucoma

Contacts and locations

Locations

  • Nicox Clinical Site

    Dothan, Alabama, 36301, United States

  • Nicox Clinical Site

    Chandler, Arizona, 85224, United States

  • Nicox Clinical Site

    Phoenix, Arizona, 85003, United States

  • Nicox Clinical Site

    Burbank, California, 91505, United States

  • Nicox Clinical Site

    Garden Grove, California, 92843, United States

  • Nicox Clinical Site

    Huntington Beach, California, 92647, United States

  • Nicox Clinical Site

    La Jolla, California, 92037, United States

  • Nicox Clinical Site

    Murrieta, California, 92562, United States

  • Nicox Clinical Site

    Newport Beach, California, 92663, United States

  • Nicox Clinical Site

    Pasadena, California, 91107, United States

  • Nicox Clinical Site

    Petaluma, California, 94954, United States

  • Nicox Clinical Site

    Redlands, California, 92373, United States

  • Nicox Clinical Site

    San Francisco, California, 94115, United States

  • Nicox Clinical Site

    Danbury, Connecticut, 06810, United States

  • Nicox Clinical Site

    Boynton Beach, Florida, 33437, United States

  • Nicox Clinical Site

    Delray Beach, Florida, 33484, United States

  • Nicox Clinical Site

    Fort Lauderdale, Florida, 33309, United States

  • Nicox Clinical Site

    Fort Myers, Florida, 33901, United States

  • Nicox Clinical Site

    Jacksonville, Florida, 32256, United States

  • Nicox Clinical Site

    Jupiter, Florida, 33477, United States

  • Nicox Clinical Site

    Lakeland, Florida, 33805, United States

  • Nicox Clinical Site

    Largo, Florida, 33770, United States

  • Nicox Clinical Site

    Mt. Dora, Florida, 32757, United States

  • Nicox Clinical Site

    Venice, Florida, 34285, United States

  • Nicox Clinical Site

    Morrow, Georgia, 30260, United States

  • Nicox Clinical Site

    Roswell, Georgia, 30076, United States

  • Nicox Clinical Site

    Peoria, Illinois, 61615, United States

  • Nicox Clinical Site

    Rock Island, Illinois, 61201, United States

  • Nicox Clinical Site

    Indianapolis, Indiana, 46202, United States

  • Nicox Clinical Site

    Bangor, Maine, 04401, United States

  • Nicox Clinical Site

    Boston, Massachusetts, 02114, United States

  • Nicox Clinical Site

    Lancaster, Massachusetts, 01523, United States

  • Nicox Clinical Site

    Grand Rapids, Michigan, 49546, United States

  • Nicox Clinical Site

    Chaska, Minnesota, 55318, United States

  • Nicox Clinical Site

    Kansas City, Missouri, 64111, United States

  • Nicox Clinical Site

    St Louis, Missouri, 63128, United States

  • Nicox Clinical Site

    Clifton Park, New York, 12065, United States

  • Nicox Clinical Site

    The Bronx, New York, 10467, United States

  • Nicox Clinical Site

    Troy, New York, 12180, United States

  • Nicox Clinical Site

    Asheville, North Carolina, 28803, United States

  • Nicox Clinical Site

    Winston-Salem, North Carolina, 27101, United States

  • Nicox Clinical Site

    Fargo, North Dakota, 58103, United States

  • Nicox Clinical Site

    Cincinnati, Ohio, 45236, United States

  • Nicox Clinical Site

    Cincinnati, Ohio, 45242, United States

  • Nicox Clinical Site

    Eugene, Oregon, 97401, United States

  • Nicox Clinical Site

    Cranberry Township, Pennsylvania, 16066, United States

  • Nicox Clinical Site

    Kingston, Pennsylvania, 18704, United States

  • Nicox Clinical Site

    Memphis, Tennessee, 38119, United States

  • Nicox Clinical Site

    Memphis, Tennessee, 38120, United States

  • Nicox Clinical Site

    Austin, Texas, 78731, United States

  • Nicox Clinical Site

    El Paso, Texas, 79922, United States

  • Nicox Clinical Site

    Houston, Texas, 77008, United States

  • Nicox Clinical Site

    Houston, Texas, 77025, United States

  • Nicox Clinical Site

    Mission, Texas, 78572, United States

  • Nicox Clinical Site

    San Antonio, Texas, 78212, United States

  • Nicox Clinical Site

    San Antonio, Texas, 78229, United States

  • Nicox Clinical Site

    San Antonio, Texas, 78238, United States

  • Nicox Clinical Site

    Sugar Land, Texas, 77479, United States

  • Nicox Clinical Site

    St. George, Utah, 84790, United States

  • Nicox Clinical Site

    Falls Church, Virginia, 22042, United States

  • Nicox Clinical Site

    Bellevue, Washington, 98004, United States

  • Nicox Clinical Site

    Seattle, Washington, 98104, United States

  • Nicox Clinical Site

    Seattle, Washington, 98125, United States

  • Nicox Clinical Site

    Lanzhou, Gansu, 730030, China

  • Nicox Clinical Site

    Shantou, Guangdong, 515401, China

  • Nicox Clinical Site

    Harbin, Heilongjiang, 150086, China

  • Nicox Clinical Site

    Zhengzhou, Henan, 450003, China

  • Nicox Clinical Site

    Zhengzhou, Henan, 450052, China

  • Nicox Clinical Site

    Wuhan, Hubei, 430060, China

  • Nicox Clinical Site

    Yichang, Hubei, 443003, China

  • Nicox Clinical Site

    Changsha, Hunan, 410011, China

  • Nicox Clinical Site

    Changsha, Huna, 410015, China

  • Nicox Clinical Site

    Nanchang, Jiangxi, 330006, China

  • Nicox Clinical Site

    Changchun, Jilin, 130021, China

  • Nicox Clinical Site

    Dalian, Liaoning, 116091, China

  • Nicox Clinical Site

    Xi'an, Shaanxi, 710004, China

  • Nicox Clinical Site

    Jinan, Shandong, 250002, China

  • Nicox Clinical Site

    Qingdao, Shandong, 266071, China

  • Nicox Clinical Site

    Chengdu, Sichuan, 610041, China

  • Nicox Clinical Site

    Wenzhou, Xhejiang, 325027, China

  • Nicox Clinical Site

    Beijing, 100005, China

  • Nicox Clinical Site

    Beijing, 100191, China

  • Nicox Clinical Site

    Chongqing, 400020, China

  • Nicox Clinical Site

    Shanghai, 200011, China

  • Nicox Clinical Site

    Shanghai, 200031, China

  • Nicox Clinical Site

    Shanghai, 200040, China

  • Nicox Clinical Site

    Tianjing, 300020, China

  • Nicox Clinical Site

    Tianjing, 300384, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.